Compare
Exelixis vs Gilead Sciences (EXEL vs GILD)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Exelixis (EXEL) returned +72.3% and Gilead Sciences (GILD) +36.1%; so far this year the figures are +58.7% and +36.0%.
Gilead Sciences is the larger company by market value, about 12.2 times the size of Exelixis.
Revenue grew +9.1% at EXEL and +6.5% at GILD over the last year.
EXEL pays no dividend. GILD yields 1.95%.
Data as of the latest close. Not investment advice.
Relative performance
| EXEL | GILD | |
|---|---|---|
| Price | $69.57 | $166.89 |
| 1-day | +1.25% | -0.41% |
| YTD | +58.73% | +35.97% |
| 1 year | +72.33% | +36.15% |
| 3 years | +230.97% | +108.12% |
| Market cap | $17.0B | $207.0B |
| P/E | 20.8 | — |
| P/S | 6.80 | 6.68 |
| P/B | 9.26 | 15.87 |
| Revenue growth | +9.10% | +6.50% |
| EPS growth | +40.90% | -149.00% |
| Gross margin % | 96.3 | 79.9 |
| Net margin % | 35.5 | -12.5 |
| ROE % | 48.3 | -29.6 |
| Debt / equity | 0.10 | 2.01 |
| FCF yield % | 6.8 | 6.7 |
| Dividend yield % | — | 1.95 |
| Beta | 0.61 | 0.37 |
| RSI (14) | 66.0 | 60.2 |
| Technical rating |